Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
EPZM > SEC Filings for EPZM > Form 10-Q on 1-Aug-2013All Recent SEC Filings

Show all filings for EPIZYME, INC. | Request a Trial to NEW EDGAR Online Pro

Form 10-Q for EPIZYME, INC.


1-Aug-2013

Quarterly Report


Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Forward-looking Information

This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. These statements may be identified by such forward-looking terminology as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar statements or variations of such terms. Our forward-looking statements are based on a series of expectations, assumptions, estimates and projections about the Company, are not guarantees of future results or performance and involve substantial risks and uncertainty. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding:

• our plans to develop and commercialize personalized therapeutics for patients with genetically defined cancers;

• our ongoing and planned clinical trials, including the timing of anticipated results;

• our ability to receive research funding and achieve anticipated milestones under our collaborations;

• the timing of and our ability to obtain and maintain regulatory approvals for our product candidates;

• the rate and degree of market acceptance and clinical utility of our products;

• our commercialization, marketing and manufacturing capabilities and strategy;

• our intellectual property position;

• our ability to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives; and

• our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.

All of our forward-looking statements are as of the date of this Quarterly Report on Form 10-Q only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of or any material adverse change in one or more of the risk factors or risks and uncertainties referred to in this Quarterly Report on Form 10-Q or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the SEC could materially and adversely affect our business, prospects, financial condition and results of operations. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Quarterly Report on Form 10-Q, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Quarterly Report on Form 10-Q which modify or impact any of the forward-looking statements contained in this Quarterly Report on Form 10-Q will be deemed to modify or supersede such statements in this Quarterly Report on Form 10-Q.

Management Overview

Epizyme, Inc. ("we," "us," "our," "Epizyme" or the "Company") is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative personalized therapeutics for patients with genetically defined cancers. We have built a proprietary product platform that we use to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic. Our therapeutic strategy is to inhibit the incorrect function of oncogenic HMTs in order to treat the underlying causes of the associated genetically defined cancers. The three months ended June 30, 2013 and 2012 are referred to as the second quarter of 2013 and 2012, respectively. Unless the context indicates otherwise, all references herein to the Company, we, us and our, include the Company and its wholly-owned subsidiary.

Our management's discussion and analysis of our financial condition and results of operations are based upon our unaudited consolidated financial statements included in this Quarterly Report on Form 10-Q, which have been prepared by us in accordance with accounting principles generally accepted in the United States of America, or GAAP, for interim periods and


Table of Contents

with Regulation S-X promulgated under the Securities Exchange Act of 1934, as amended. This discussion and analysis should be read in conjunction with these unaudited consolidated financial statements and the notes thereto as well as in conjunction with our Prospectus filed pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended, (the "Securities Act") with the Securities and Exchange Commission ("SEC") on May 31, 2013, which we refer to as the Prospectus.

We commenced active operations in early 2008, and since inception, have incurred significant operating losses. As we are a clinical stage company, we expect to continue to incur significant expenses and operating losses over the next several years. Since our inception and through June 30, 2013, we have raised an aggregate of $283.3 million to fund our operations, of which $124.8 million was through our collaboration agreements, $82.5 million was from our initial public offering, which we completed in June 2013, and $76.0 million was from the sale of redeemable convertible preferred stock, which automatically converted to common stock upon the closing of our initial public offering. Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity or debt financings and collaboration agreements.

We believe we are the first company to conduct a clinical trial of an HMT inhibitor. We are conducting both a Phase I clinical trial of our most advanced product candidate, EPZ-5676, an inhibitor targeting the DOT1L HMT, for the treatment of mixed lineage leukemia, or MLL-r, a genetically defined subtype of the two most common forms of acute leukemia, as well as a Phase I/II clinical trial of our second most advanced product candidate, EPZ-6438, an inhibitor targeting the EZH2 HMT, for the treatment of a genetically defined subtype of non-Hodgkin lymphoma. We also have a pipeline of other HMT inhibitors that are in preclinical development.

The clinical development plan for each of our therapeutic product candidates is directed towards patients with a particular genetically defined cancer. For each therapeutic product candidate, we intend to develop a companion diagnostic. We plan to include patients with the particular genetically defined cancer in our clinical trials beginning in Phase I with a view to assessing possible early evidence of potential therapeutic effect. As we are tailoring our personalized therapeutics for discrete patient populations with genetically defined cancers, we believe that many of our products may qualify for orphan drug designation in the United States and the European Union.

We have entered into strategic collaborations for certain of our therapeutic programs and corresponding companion diagnostics. Our three primary collaboration partners for our therapeutic programs are Celgene Corporation and Celgene International Sàrl, collectively, Celgene; Eisai Co., Ltd., or Eisai; and Glaxo Group Limited, an affiliate of GlaxoSmithKline, or GSK. We retain all product rights in the United States under the Celgene collaboration and an opt-in right to co-develop, co-commercialize and share profits as to licensed products in the United States under the Eisai collaboration.

The following table summarizes key information about our two most advanced clinical programs, including the role of our collaboration partners:

Product                            Indication                                                        Diagnostic
Candidate     Description     (Genetic Alteration)   Stage of Development   Commercial Rights       Collaborator

EPZ-5676    DOT1L inhibitor   MLL-r subtype of       Phase I clinical       Epizyme: United      Abbott Molecular
                              acute myeloid          trial ongoing          States Celgene:      Inc., or Abbott
                              leukemia, or AML,                             Rest of world
                              and acute
                              lymphoblastic
                              leukemia, or ALL
                              (Chromosomal
                              translocation
                              involving the MLL
                              gene)

EPZ-6438    EZH2 inhibitor    Non-Hodgkin lymphoma   Phase I/II clinical    Eisai: Worldwide     Roche Molecular
                              and potentially        trial ongoing          rights, subject to   Systems, Inc., or
                              other solid tumors                            Epizyme's opt-in     Roche
                              (Point mutation in                            on 50.0% of United
                              EZH2)                                         States rights

In the six months ended June 30, 2013 we continued enrollment in the dose escalation stage of our Phase I clinical trial of EPZ-5676, received notification that our clinical trial application was approved in France and enrolled the first patient in a Phase I/II clinical trial of EPZ-6438, which Eisai refers to as E7438, there, continued to identify additional indications for our clinical stage product candidates, such as the potential development of EPZ-6438 for the treatment of patients with malignant rhabdoid


Table of Contents

tumors, and continued to progress the three target programs partnered with GSK as well as a number of other research programs directed to high priority HMTs in our pipeline. During the second half of 2013, we expect to complete the dose escalation stage of our Phase I clinical trial for EPZ-5676 and initiate the expansion stage of this trial which will only include patients with MLL-r.

The key terms of our primary collaboration agreements are as follows:

• Celgene

In April 2012, we entered into a collaboration and license agreement with Celgene, to discover, develop and commercialize, in all countries other than the United States, small molecule HMT inhibitors targeting DOT1L, including EPZ-5676, and any other HMT targets from our product platform for patients with genetically defined cancers, excluding targets already selected by our two other existing collaborations, which we refer to as the available targets.

Agreement Structure

Under the terms of the agreement, we received a $65.0 million upfront payment and $25.0 million from the sale of our series C redeemable convertible preferred stock to an affiliate of Celgene. In addition, we are eligible to earn up to $60.0 million in clinical development milestone payments and up to $100.0 million in regulatory milestone payments related to DOT1L. We are also eligible to earn up to $65.0 million in payments, including a combination of clinical development milestone payments and an option exercise fee, and up to $100.0 million in regulatory milestone payments for each available target as to which Celgene exercises its option during an initial option period ending in July 2015. Celgene has the right to extend the option period until July 2016 by making a significant option extension payment. As to DOT1L and each available target as to which Celgene exercises its option, we retain all product rights in the United States and are eligible to receive royalties for each target at defined percentages ranging from the mid-single digits to the mid-teens on net product sales outside of the United States, subject to reductions in specified circumstances. Due to the uncertainty of pharmaceutical development and the high historical failure rates generally associated with pharmaceutical development, we may not receive any milestone or royalty payments from Celgene. The first potential milestone payment that we might be entitled to receive under this agreement is $25.0 million for achieving proof-of-concept, as defined in the agreement, for our DOT1L inhibitor.

We are obligated to conduct and solely fund research and development costs of the Phase I clinical trials for the DOT1L target and through the effectiveness of the first investigational new drug application for an HMT inhibitor directed to each available target selected by Celgene, after which Celgene and we will equally co-fund global development and each party will solely fund territory-specific development costs for its territory.

Collaboration Revenue Recorded

Through June 30, 2013, in addition to amounts allocated to Celgene's purchase of shares of our series C redeemable convertible preferred stock, we had received a total of $68.0 million in upfront payments under the Celgene agreement, including a $3.0 million implied premium on Celgene's purchase of our series C redeemable convertible preferred stock. Through June 30, 2013, we have recognized $31.1 million of collaboration revenue in the consolidated statements of operations and comprehensive (loss) income related to this agreement, including $3.6 million and $7.2 million in the three and six months ended June 30, 2013, respectively, and $13.6 million in the three and six months ended June 30, 2012. As of June 30, 2013 and December 31, 2012, we had deferred revenue of $36.9 million and $44.1 million, respectively, related to this agreement.

• Eisai

In April 2011, we entered into a collaboration and license agreement with Eisai under which we granted Eisai an exclusive worldwide license to our small molecule HMT inhibitors directed to EZH2, including EPZ-6438, while retaining an opt-in right to co-develop, co-commercialize and share profits with Eisai as to licensed products in the United States. Additionally, as part of the research collaboration, we agreed to provide research and development services related to the licensed compounds through December 31, 2014.


Table of Contents

Agreement Structure

Under the terms of the agreement, we have recorded a $3.0 million upfront payment, $7.0 million in preclinical research and development milestone payments, a $6.0 million clinical development milestone achieved in June 2013 and received in July 2013, and cash and accounts receivable of $15.0 million for research and development services through June 30, 2013. We are eligible to earn up to $25.0 million in additional clinical development milestone payments, up to $55.0 million in regulatory milestone payments and up to $115.0 million in sales-based milestone payments. We are also eligible to receive royalties at a percentage in the mid-single digits on any net product sales outside of the United States and at a percentage from the mid-single digits to low double-digits on any net product sales in the United States, subject to reduction in specified circumstances. Due to the uncertainty of pharmaceutical development and the high historical failure rates generally associated with pharmaceutical development, we may not receive any additional milestone payments or royalty or profit share payments from Eisai. The next potential milestone payment that we might be entitled to receive under this agreement is $10.0 million for the initiation of the Phase II portion the Phase I/II clinical trial.

Eisai solely funds all research, development and commercialization costs for licensed compounds, except for the cost obligations that we will undertake if we exercise our opt-in right to co-develop, co-commercialize and share profits with Eisai as to licensed products in the United States. If we exercise our opt-in right as to a licensed compound, the licensed compound would become a shared product as to which Eisai's obligation to pay royalties to us as to such shared product in the United States will terminate; Eisai and we will share in net profits or losses with respect to such shared product in the United States; 25.0% of specified past development costs will become creditable by Eisai against future milestones or royalties due to us, subject to specified limitations; Eisai and we will share equally in subsequent development costs allocated to the United States; and all subsequent milestone payments that become payable by Eisai to us based on the shared product will be decreased by 50.0%.

Collaboration Revenue Recorded

Through June 30, 2013, we have recorded a total of $31.0 million in cash and accounts receivable and have recognized $28.6 million of collaboration revenue in the consolidated statements of operations and comprehensive (loss) income related to this agreement, including $8.2 million and $10.5 million in the three and six months ended June 30, 2013, respectively, and $1.7 million and $7.4 million in the three and six months ended June 30, 2012, respectively, with a $6.0 million clinical development milestone achieved recognized as collaboration revenue in the three and six months ended June 30, 2013 and a $4.0 million research milestone achieved and recognized as collaboration revenue in the six months ended June 30, 2012. As of June 30, 2013 and December 31, 2012, we had deferred revenue of $2.4 million and $3.2 million, respectively, related to this agreement.

• GSK

In January 2011, we entered into a collaboration and license agreement with GSK to discover, develop and commercialize novel small molecule HMT inhibitors directed to available targets from our product platform. Under the terms of the agreement, we granted GSK the option to obtain exclusive worldwide license rights to HMT inhibitors directed to up to three targets. GSK selected three targets, and the term during which it was entitled to select targets expired in July 2012.

Agreement Structure

Under the agreement, we have received a $20.0 million upfront payment, $8.0 million in preclinical research and development milestone payments and $5.3 million of fixed research funding through June 30, 2013. We are entitled to receive an additional $0.7 million in fixed research funding in 2013 and are eligible to receive up to $21.0 million in additional preclinical research and development milestone payments, up to $99.0 million in clinical development milestone payments, up to $240.0 million in regulatory milestone payments and up to $270.0 million in sales-based milestone payments. In addition, GSK is required to pay us royalties at percentages from the mid-single digits to the low double-digits, on a licensed product-by-licensed product basis, on worldwide net product sales, subject to reductions in specified circumstances. Due to the uncertainty of pharmaceutical development and the high historical failure rates generally associated with pharmaceutical development, we may not receive any additional milestone payments or royalty payments from GSK. The next potential milestone payment that we might be entitled to receive under this agreement is a research milestone. However, due to the varying stages of development of each licensed target, we are not able to determine the next milestone that might be achieved, if any.


Table of Contents

For each selected target in the collaboration, we are primarily responsible for research until the selection of the development candidate, and GSK will be solely responsible for subsequent development and commercialization. We are responsible for providing research and development services with respect to the selected targets pursuant to agreed upon research plans during a research term that ends in January 2015. GSK is providing a fixed amount of research funding during the second and third years of the research term. GSK is obligated to provide research funding equal to 100.0% of research and development costs, subject to specified limitations, for any research activities we conduct in the fourth year of the research term.

Collaboration Revenue Recorded

Through June 30, 2013, we received a total of $33.3 million in payments under the GSK agreement and have recognized $15.7 million of collaboration revenue in the consolidated statements of operations and comprehensive (loss) income related to this agreement, including $3.0 million and $6.0 million in the three and six months ended June 30, 2013, respectively. We did not recognize any collaboration revenue in the three and six months ended June 30, 2012 related to this agreement as none of the delivered elements of the arrangement had standalone value at that time apart from the undelivered elements of the arrangement. As of June 30, 2013 and December 31, 2012, we had deferred revenue of $17.6 million and $22.0 million, respectively, related to this agreement.

Collaboration Revenue

The following is a comparison of collaboration revenue for the three and six months ended June 30, 2013 and 2012:

Three Months Ended June 30, Six Months Ended June 30, 2013 2012 Decrease 2013 2012 Increase

(In millions) (In millions)

Collaboration revenue $ 14.8 $ 15.3 $ (0.5 ) $ 23.7 $ 21.0 $ 2.7

Through June 30, 2013, our revenue consisted of collaboration revenue, including amounts recognized from deferred revenue related to upfront payments for licenses or options to obtain licenses in the future, research and development funding and milestone payments earned under collaboration and license agreements with our collaboration partners.

During the second quarter of 2013, collaboration revenue consisted of $6.4 million recognized from deferred revenue related to upfront payments for licenses, $6.0 million in milestone payments and $2.4 million in research and development funding. This revenue compares to $14.0 million recognized from deferred revenue related to upfront payments for licenses and $1.3 million in research and development funding recognized in the second quarter of 2012.

Collaboration revenue recognized from deferred revenue in the second quarter of 2013 comprised $3.6 million under our Celgene agreement, $0.4 million under our Eisai agreement and $2.4 million under our GSK agreement, as compared to $13.6 million under our Celgene agreement and $0.4 million under our Eisai agreement in the second quarter of 2012. Milestone revenue in the second quarter of 2013 represents a $6.0 million clinical development milestone achieved under our Eisai agreement in June 2013. Collaboration revenue recognized for research and development services in the second quarter of 2013 comprised $1.8 million under our Eisai agreement and $0.6 million under our GSK agreement, as compared to $1.3 million under our Eisai agreement in the second quarter of 2012.

During the six months ended June 30, 2013, collaboration revenue consisted of $12.8 million recognized from deferred revenue related to upfront payments for licenses, $6.0 million in milestone payments and $4.9 million in research and development funding. This revenue compares to $14.4 million recognized from deferred revenue related to upfront payments for licenses, $4.0 million in milestone payments and $2.6 million in research and development funding recognized in the six months ended June 30, 2012.


Table of Contents

Collaboration revenue recognized from deferred revenue in the six months ended June 30, 2013 comprised $7.2 million under our Celgene agreement, $0.8 million under our Eisai agreement and $4.8 million under our GSK agreement, as compared to $13.6 million under our Celgene agreement and $0.8 million under our Eisai agreement in the same period of the prior year. Milestone revenue in the six months ended June 30, 2013 represents a $6.0 million clinical development milestone achieved under our Eisai agreement, as compared to a $4.0 million preclinical research and development milestone achieved under Eisai agreement in the same period of the prior year. Collaboration revenue recognized for research and development services in the six months ended June 30, 2013 comprised $3.7 million under our Eisai agreement and $1.2 million under our GSK agreement, as compared to $2.6 million under our Eisai agreement in the same period of the prior year.

Research and Development

The following is a comparison of research and development expenses for the three and six months ended June 30, 2013 and 2012:

Three Months Ended June 30, Six Months Ended June 30, 2013 2012 Increase 2013 2012 Increase

(In millions) (In millions)

Research and development $ 13.9 $ 8.9 $ 5.0 $ 27.3 $ 18.1 $ 9.2

Research and development expenses consist of expenses incurred in performing research and development activities, including compensation and benefits for full-time research and development employees, facilities expenses, overhead expenses, clinical trial and related clinical manufacturing expenses, fees paid to third party clinical research organizations, or CROs, and other outside expenses. As we advance our product platform, we are conducting research on several prioritized HMT targets. Our research and development team is organized such that the strategy, design, management and evaluation of results of all of our research and development plans is accomplished internally while some of our research and development activities are executed using our multinational network of CROs. In the early phases of development, our research and development costs are often devoted to enhancing our product platform and are not necessarily allocable to specific targets.

The following table illustrates the components of our research and development expenses:

                                                                 Three Months Ended June 30,                 Six Months Ended June 30,
Product Program (Phase as of the latest period end)              2013                    2012                 2013                  2012
                                                                        (In millions)                              (In millions)
External research and development expenses:
EPZ-5676 (Phase I) and related DOT1L programs               $          2.9           $        2.3         $         6.0           $    5.3
EPZ-6438 (Phase I/II) and related EZH2 programs                        1.1                    0.7                   2.3                1.6
Discovery and preclinical stage product programs,
collectively                                                           5.2                    2.8                  10.0                5.6
Internal research and development expenses                             4.7                    3.1                   9.0                5.6

Total research and development expenses                     $         13.9           $        8.9         $        27.3           $   18.1

. . .

  Add EPZM to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for EPZM - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.